ClinicalTrials.gg
CompletedNCT00327990Updated May 30, 2017

Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate

A Phase 4 interventional study of Ibandronate and Alendronate in Osteoporosis, sponsored by GlaxoSmithKline. Completed at 38 sites in Netherlands. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
60 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Ibandronic Acid in Osteoporosis — 2 open to participants now, 2 under way, none of them phase 3. Ibandronic Acid · Osteoporosis.

Enrollment
4th of 16
300 · median 100
Started
2005
with 2 others
Phase 4
8 of 16
1 open now
Registered
3rd of 16
by date
Lead sponsor
3 of 16
GlaxoSmithKline

Among the 16 studies testing Ibandronic Acid in Osteoporosis, this one is the 4th largest by enrollment, is one of 3 that started in 2005, is one of 8 in phase 4, and was the 3rd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 16 studies testing Ibandronic Acid in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Ibandronic Acid

Ibandronic Acid: first FDA approval 2003 (BONIVA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 60 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Ibandronic Acid in Osteoporosis, or all of them as a file.
02

Study summary

This is a two part study (screening and treatment). The first part (screening) is designed to evaluate the percentage of patients missed in diagnosing osteoporosis by general practitioners (GP's). The second part (treatment) is designed to determine the preference by patients for the once monthly ibandronate or the once weekly alendronate.

Read the detailed description

A multi-centre, randomised, open-label, cross-over study to evaluate the percentage of false negative osteoporosis diagnoses using the standard case-finding procedure as described by the Dutch Institute for Health Care (CBO) and to determine the preference of adult osteoporosis patients between once monthly dosing of ibandronate (150 mg) and once weekly dosing of alendronate (70 mg).

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • ibandronate
  • osteoporosis
  • preference
  • case-finding
  • post-menopausal
  • alendronate
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women registered with a GP, without a prior history of osteoporosis. According to a case-finding procedure, osteoporosis will be diagnosed or excluded.

Exclusion criteria

Exclusion criteria:

  • Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia.
  • Inability to stand or sit in the upright position for 60 minutes.
  • Previous use of bone active agents (e.g. strontium, PTH).
  • Significant medical condition which may preclude the patient's ability to complete the study.
  • History of alcohol or drug abuse.
  • to any component of the bisphosphonates alendronate and ibandronate.
  • Administration of any drug within 30 days preceding the first dose of the study drug.
  • Serum total calcium > 10.5 mg/dL or \< 8.0 mg/dL (equivalent to 2.63 mmol/L and 1.99 mmol/L).
  • Osteoporosis by secondary causes, will be excluded especially when an isolated deformity of the vertebral body is detected during x-ray analysis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
300 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of patients falsely not diagnosed with osteoporosis using the standard case-finding and additional X-ray procedure in GP practice. Part 2: Patient preference for once monthly ibandronate or once weekly alendronate

Secondary outcomes

  1. Part 1: To assess the safety and tolerance of both ibandronate and alendronate. Part 2: To assess patient preference in reminder methods during once monthly ibandronate regimen: postcard, text message or telephone patient relationship program.

07

Study locations

38 sites
  • GSK Investigational Site
    Bennebroek, 2121 BB, Netherlands
  • GSK Investigational Site
    Breda, 4834 AD, Netherlands
  • GSK Investigational Site
    Damwoude, 9104 GJ, Netherlands
  • GSK Investigational Site
    Den Haag, 2544 KM, Netherlands
  • GSK Investigational Site
    Den Haag, 2582 LJ, Netherlands
  • GSK Investigational Site
    Den Haag, 2584 HV, Netherlands
  • GSK Investigational Site
    Driebergen-rijsenburg, 3972 WG, Netherlands
  • GSK Investigational Site
    Easterein, 8734 CG, Netherlands
  • GSK Investigational Site
    Eersel, 5521 CD, Netherlands
  • GSK Investigational Site
    Eindhoven, 5613 BE, Netherlands
  • GSK Investigational Site
    Enschede, 7544 NZ, Netherlands
  • GSK Investigational Site
    Etten-leur, 4872 LA, Netherlands
  • GSK Investigational Site
    Geleen, 6163 GC, Netherlands
  • GSK Investigational Site
    Groesbeek, 6561 CM, Netherlands
  • GSK Investigational Site
    Heerlen, 6417 BR, Netherlands
  • GSK Investigational Site
    Hengelo, 7255 AM, Netherlands
  • GSK Investigational Site
    Hoogvliet, 3192 JN, Netherlands
  • GSK Investigational Site
    Hoogwoud, 1718 BG, Netherlands
  • GSK Investigational Site
    Hulst, 4561 CJ, Netherlands
  • GSK Investigational Site
    Landgraaf, 6373 JS, Netherlands
  • GSK Investigational Site
    Losser, 7581 BV, Netherlands
  • GSK Investigational Site
    Midwoud, 1679 GJ, Netherlands
  • GSK Investigational Site
    Nijverdal, 7442 LS, Netherlands
  • GSK Investigational Site
    Nunspeet, 8071 LX, Netherlands
  • GSK Investigational Site
    Oldebroek, 8096 AV, Netherlands
  • GSK Investigational Site
    Oudenbosch, 4731 MA, Netherlands
  • GSK Investigational Site
    Poortvliet, 4693 BT, Netherlands
  • GSK Investigational Site
    Prinsenbeek, 4841 RR, Netherlands
  • GSK Investigational Site
    Raalte, 8101 ZW, Netherlands
  • GSK Investigational Site
    Ridderkerk, 2985 VG, Netherlands
  • GSK Investigational Site
    Rotterdam, 3082 DC, Netherlands
  • GSK Investigational Site
    Spijkenisse, 3207 NB, Netherlands
  • GSK Investigational Site
    Tilburg, 5038 DE, Netherlands
  • GSK Investigational Site
    Voerendaal, 6367 ED, Netherlands
  • GSK Investigational Site
    Wassenaar, 2241 KE, Netherlands
  • GSK Investigational Site
    Wildervank, 9648 BE, Netherlands
  • GSK Investigational Site
    Woerden, 3443 GG, Netherlands
  • GSK Investigational Site
    Zaandam, 1504 JA, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2006
First posted
May 19, 2006
Start
Apr 2005
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00327990
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 19, 2006
Start date
Apr 2005
Primary completion
Dec 2006
Completion
Dec 2006
Last update
May 30, 2017

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibandronic Acid · Alendronate

Start the discussion